Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Zeno. This analysis is provided for institutional research purposes only and is not investment advice.
"Zeno argues Danaher is a high-quality compounder trading at a discount despite market-leading positions across Biotechnology, Diagnostics, and Life Sciences. The Biotechnology segment is the crown jewel with 88% recurring revenues and 40% EBIT margins, particularly dominant in chromatography purification."
Zeno Equity Partners presents a detailed investment thesis on Danaher, their largest position, arguing it exemplifies their strategy of identifying companies with market power, sustainable high returns, and a founder's mindset focused on disciplined capital allocation. Danaher operates across three healthcare segments: Biotechnology (30% of revenues, 40% of profits), Diagnostics (40% of both), and Life Sciences (20% of profits), all benefiting from secular growth trends in aging populations, rising disease incidence, and technological advances. The Biotechnology segment, operating under the Cytiva brand, is described as the crown jewel with 88% recurring revenues and industry-leading 40% EBIT margins, particularly strong in chromatography purification with ~70% market share. Diagnostics demonstrates strong switching costs and vendor reputation barriers with 29% EBIT margins. The manager acknowledges mistakes in Life Sciences, particularly the Aldevron and Abcam acquisitions which have destroyed value. Despite recent headwinds from COVID normalization, biotech funding winter, China pricing pressure, and Trump administration policies, the manager believes these events have delayed rather than derailed returns. At a ~5% free-cash-flow yield with expected high-single-digit to low-double-digit earnings growth over the next decade, the manager views Danaher as offering compelling risk-adjusted returns.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
